Triplet Tx Ups Survival in BRAF V600E-Mutated Colorectal Cancer

FRIDAY, Oct. 4, 2019 -- A triplet combination of therapies (encorafenib, cetuximab, and binimetinib) results in significantly longer overall survival and a higher response rate than standard therapy in patients with metastatic colorectal cancer with...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news